RxDoctor Payments Data

Paul Peters, MD

Orthopaedic Surgery · Dallas, TXNPI 1356498299

Payments from drug & device makers

What this record shows

This record is dominated by royalties or licence payments: $197,687 of the $198,672 with a category attached, or 99.5%. Depuy Synthes Products, Inc. accounts for 99.5% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $46,599 and has fallen 99.6% since, to $176 in 2025. Among orthopaedic surgery clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$198,672in general payments, 2019–2025

Across 46 payments — averaging $4318.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Depuy Synthes Products, Inc.$198K
  • Stryker$675
  • Heron Therapeutics, Inc.$126
  • Medical Device Business Services, Inc.$83
  • Johnson & Johnson$51
  • Molnlycke Health Care US, LLC$27
  • plus $23 from 1 others
$25,000in research payments, 2019–2025

Across 5 payments — averaging $5000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medical Device Business Services, Inc.$25K

What the payments were for

  • Royalty or licence$197,687100%
  • Food & beverage$9850%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$198,672 in reported general payments places this provider in the 90th percentile of 1,337 orthopaedic surgery providers in Texas.

See all orthopaedic surgery providers in Texas →

Medicare billing

Part B allowed, 2024
$508,340
Medicare patients
810
Services billed
20,551

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban67$27,743
Celecoxib295$7,228
Meloxicam520$2,849
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen192$2,464
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen71$1,174
Methylprednisolone185$1,063
Cephalexin56$894
Amoxicillin326$765
Tramadol Hcl110$438
Ondansetron OdtOndansetron27$287
SsdSilver Sulfadiazine23$138
Clindamycin Hcl27$93

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery in Dallas

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →